Screening for Hepatitis C Virus: How Universal Is Universal?

Ravi Jhaveri*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

In March and April of 2020, public health authorities issued major updates to screening recommendations for hepatitis C virus infection. With the rise in cases driven by injection drug use coupled with access to highly effective therapies promising a cure, all adults aged ≥18 years should receive one-time hepatitis C virus antibody screening in any health care setting. Although the recommendation is dubbed “universal,” this commentary reviews the details of the recommendations and discusses the high-risk populations not entirely captured with these changes.

Original languageEnglish (US)
Pages (from-to)1434-1441
Number of pages8
JournalClinical Therapeutics
Volume42
Issue number8
DOIs
StatePublished - Aug 2020

Keywords

  • baby boomers
  • hepatitis C virus
  • injection drug use
  • pregnant women
  • screening
  • young adults

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Screening for Hepatitis C Virus: How Universal Is Universal?'. Together they form a unique fingerprint.

Cite this